1. Home
  2. AMTB vs CSTL Comparison

AMTB vs CSTL Comparison

Compare AMTB & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

N/A

Current Price

$20.49

Market Cap

776.2M

Sector

Finance

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$39.79

Market Cap

661.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMTB
CSTL
Founded
1979
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
776.2M
661.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
AMTB
CSTL
Price
$20.49
$39.79
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$21.75
$40.67
AVG Volume (30 Days)
251.0K
455.3K
Earning Date
01-21-2026
11-03-2025
Dividend Yield
1.76%
N/A
EPS Growth
N/A
N/A
EPS
1.59
N/A
Revenue
$388,504,000.00
$343,530,000.00
Revenue This Year
$61.42
$1.69
Revenue Next Year
$2.10
N/A
P/E Ratio
$12.82
N/A
Revenue Growth
51.98
10.15
52 Week Low
$15.62
$14.59
52 Week High
$25.03
$40.61

Technical Indicators

Market Signals
Indicator
AMTB
CSTL
Relative Strength Index (RSI) 70.85 72.69
Support Level $20.31 $37.76
Resistance Level $21.00 $39.53
Average True Range (ATR) 0.49 1.31
MACD 0.12 -0.40
Stochastic Oscillator 76.96 78.65

Price Performance

Historical Comparison
AMTB
CSTL

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: